09.23.24 -- Is Your Intellectual Property Safe With Indian CROs And CDMOs?

In the last entry of our client checklist series, we delve into crucial aspects such as project management, decision-making, MSA negotiations, and building trust in CDMO-client partnerships.

Learn how the use of human PSCs as starting materials for cell therapies is shifting and the potential PSCs hold to reduce cell variability and costs associated with cell line development.

Advancements in viral vector design and manufacturing have yielded significant improvements in key areas. Download the E-Book to keep abreast of innovations in this dynamic and rapidly evolving space.

Developers often aim to cut expenses during development. Discover the long-term outcomes of cost-effective measures like using RUO leukopaks compared to investing in high-quality GMP-grade vectors.

See how leveraging platform processes can enable flexible service at each level – pre-clinical through commercial – and reduce development timelines and costs on the path to market.

Examine the challenges CGT innovators face and how adhering to GMP requirements from an early stage helps ensure successful downstream applications.

Review the benefits of a co-transcriptional capping RNA polymerase engineered to produce synthetic RNA to meet these increasing demands for safety and cost-effectiveness.

A high-performance, helper virus-free stable producer cell line is derived from proprietary high-producer HEK293 cells and is cultivated in a chemically defined, serum-free, ADCF medium in suspension.

Ensuring the safety and efficacy of cell and gene therapy treatments necessitates rigorous quality control. See how an outsourcing partner can help you deliver safe, efficacious therapies to patients.